Medical Device Reimbursement Fraud: How the Manufacturer Can Cause the Provider’s Claim

Medical device reimbursement fraud occurs when a company knowingly causes a false government payment claim through its product, sales instructions, coding advice or handling of replacement credits. The manufacturer can shape what the clinician does, what the hospital documents and what Medicare pays, while the hospital submits the bill. If you work in device sales or reimbursement, the instruction that matters may be one your company gave its customer: admit the patient, use a different code, leave out the credit. Taxpayers pay for admissions, procedures or products sold on a false premise. The false claim can begin well before it reaches a billing department.

How Does Reimbursement Work for Medical Devices?

Medicare usually pays for an implanted device inside the hospital’s procedure or inpatient payment. The manufacturer sells the device to the institution. The hospital bills Medicare for the covered care, with the device’s cost generally included in that payment.

The people making those decisions have different jobs. The surgeon may choose the brand and type of implant. Purchasing handles the hospital’s acquisition. The manufacturer or its representative supplies the product, and the hospital’s billing team submits the institutional claim. A physician’s professional claim pays for the physician’s work.

Consignment makes the connection unusually close. A hospital can have implants on its shelves that the manufacturer still owns. In these arrangements, use or implantation can trigger the sale. The surgeon’s choice moves a product out of inventory and creates the manufacturer’s revenue at the same time that the hospital provides the health care it will bill.

Authorization, Coding, Coverage and Payment

Food and Drug Administration authorization, a billing code and Medicare coverage are separate decisions. A procedure code can describe the care accurately while the claim misrepresents whether Medicare’s coverage conditions were met.

A covered implant can have its cost packaged into the procedure even when the claim reports device codes and charges. For a reimbursement team, the useful question is what the proposed code says happened and which coverage conditions the customer’s claim represents as satisfied.

When the Device Changes the Hospital’s Payment Group

A device can change an inpatient diagnosis-related group, and therefore the hospital payment, without receiving a separate payment of its own. These groups classify hospital stays for payment.

For example, the fiscal 2026 spinal-fusion grouping included a higher group reached through a major complication or a custom-made anatomically designed interbody fusion device. The selected implant could change the group. That makes the device actually used, the operative description and the group billed a consequential comparison. A product description can move money even inside a bundled payment.

How the Manufacturer Changes the Provider’s Claim

Manufacturer conduct can change the admission, the coverage facts or the description sent to the payer.

A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, distinguishes claims that misdescribe the goods or services from claims that misrepresent compliance with conditions for payment. That distinction helps explain the device cases. One customer’s problem may be the procedure code. Another’s may be the required clinical review behind an accurately described procedure.

Kyphon and Unnecessary Inpatient Admissions

Kyphon allegedly encouraged hospitals to admit kyphoplasty patients whose procedures could have been performed as outpatient care. Kyphoplasty treats certain spinal fractures. The government’s allegation was that the admission generated a higher Medicare bill.

Medtronic Spine, Kyphon’s corporate successor, agreed to a $75 million civil settlement in May 2008. The government alleged that Kyphon’s advice led hospitals to admit patients and bill for inpatient care.

A former reimbursement manager and a former regional sales manager brought the whistleblower cases. By December 2015, the Justice Department reported hospital settlements involving more than 130 hospitals and approximately $105 million, separate from the manufacturer’s settlement. The alleged advice had traveled from the manufacturer’s reimbursement and sales operation into admissions across the country.

For an insider, that makes the sales presentation and the admission record parts of the same story. What did the company tell the hospital about reimbursement, and how did the hospital use that advice when it decided where to treat the patient?

Cardiac Devices and Unmet Coverage Conditions

Medicare coverage can depend on when a device is implanted or how the clinical decision is made. The defibrillator investigation concerned timing. Cape Cod Hospital’s valve-replacement case concerned the required evaluations and documentation.

In the national defibrillator investigation, the government alleged that hospitals implanted devices during recovery periods when Medicare coverage generally required waiting. By the final announcement in February 2016, settlements involved more than 500 hospitals and more than $280 million.

The Justice Department described the historical waiting periods as 40 days after a heart attack and 90 days after bypass surgery or angioplasty. The purpose was to let heart function improve enough that an implant might become unnecessary. The chart’s dates and clinical context therefore determined whether the coverage conditions were met. An admission recommendation and an implantation date can each change payment, but they call for different evidence.

Cape Cod Hospital agreed to a $24.3 million settlement in May 2024 over transcatheter aortic valve replacement claims. The hospital admitted failing to follow applicable Medicare requirements. The case concerned required independent examinations and the documentation and sharing of clinical judgments.

In a manufacturer case, we also examine the company’s role in shaping the coverage facts or the advice that reached the provider.

THD and Paradigm Spine’s Coding Advice

A manufacturer’s coding advice can cause the provider to describe a procedure differently from what occurred. THD America allegedly encouraged surgeons to use additional or substitute CPT codes to evade denials associated with the procedure’s temporary code. The company agreed to a settlement in September 2024 concerning Medicare and Medicaid reimbursement.

The alleged instruction changed the bill the surgeon submitted. The customer’s reimbursement became part of the manufacturer’s sales proposition.

Paradigm Spine’s May 2016 settlement resolved allegations involving unapproved uses of coflex-F and false coding recommendations for coflex. A former sales representative brought the case. In the complaint, the whistleblower alleged that a consultant recognized the mismatch between the recommended code and the device:

The same complaint alleged that Paradigm omitted coverage determinations and contrary coding guidance from its marketing and training materials. That gives an insider a specific comparison: what the reimbursement team knew about payer decisions against what the sales force told customers. The version sent to the customer can be as important as the internal discussion.

Warranty Credits That Never Reach the Bill

A replacement credit changes what the hospital or federal buyer actually owes for a device. The credit can disappear at different points: the manufacturer can withhold it from the buyer, or the hospital can receive it without reporting the required payment adjustment.

The Hospital Receives the Credit

Medicare reduces payment for qualifying replacement devices supplied free or with substantial manufacturer credits. For the inpatient rule, the device must determine the payment group. Qualifying credits include full credit or credit of at least 50% of the replacement device’s cost. The hospital’s replacement record, manufacturer’s credit and submitted claim therefore have to describe the same transaction.

That is why the returns desk and accounts payable can hold evidence a clinical reviewer never sees. The patient record explains the replacement. The credit memo explains what the hospital paid. The claim shows what it asked Medicare to pay. A payment system that packages device costs still needs the credit information to make the required adjustment.

The Manufacturer Withholds the Credit

St. Jude Medical agreed to a settlement in May 2012 over allegations that it withheld warranty credits when billing the Defense Department and Veterans Affairs for replacement pacemakers and defibrillators.

Guidant’s September 2011 warranty-credit settlement addressed allegations that withheld credits or rebates inflated replacement costs to federal programs. The removed device, warranty terms and replacement invoice supplied the connection.

Direct federal purchasing is a distinct route. In the St. Jude case, federal facilities bought the replacements. The alleged overcharge sat in the manufacturer’s billing to those buyers. In the Medicare hospital-credit problem, the hospital’s claim carries the missing adjustment. Knowing who received the credit and who billed the government identifies where the money went wrong.

When the Product Behind the Claim Is Different

Sometimes the device billed for did nothing at all.

Stimwave made that connection explicit in its civil settlement admissions. The company admitted that it presented an inert plastic component, the White Stylet, as a functioning receiver. Doctors implanted it and sought additional Medicare reimbursement. The Justice Department’s announcement describes the company’s acceptance of responsibility under the civil settlement. A component that did nothing supplied the reason for an additional bill.

The defect route appears in a separate Guidant civil settlement announced in October 2013. The government alleged sales of defective implantable heart devices for Medicare patients. This concerned the products used in paid care. It was a different allegation from withholding replacement credits.

The Prometheus Group’s March 2025 civil settlement addressed another product-to-service connection. The government alleged that the manufacturer trained providers to reuse rectal sensors and catheters across patients despite single-user or single-use restrictions. Providers allegedly covered probes with a glove or condom to reduce costs. The government’s theory was that the unsafe reuse made the services ineligible for Medicare coverage.

The training instruction mattered as much as the package label. A sales or clinical-support employee could know what customers were being taught, while the provider’s records showed how the equipment was used in the billed service.

Durable Medical Equipment and the Patient Evaluation

Durable medical equipment can be billed as an item supplied to a patient, making it a separate payment route from a hospital implant. The supplier’s claim may depend on a clinical evaluation documenting the patient’s need for the equipment.

Numotion’s August 2024 settlement concerned allegations that supplier employees authored, completed or signed patient evaluations that required qualified medical professionals. The business supplying wheelchairs allegedly supplied the clinical documentation needed to justify payment as well.

That places the evaluation alongside the equipment and the claim. Who wrote it, who was supposed to perform it and how it reached the billing team can explain the supplier’s role in obtaining reimbursement. An employee handling evaluations may see the payment problem before anyone reviews the claim.

When the Product Chooser Also Gets Paid

Financial incentives can influence the clinical choice that produces the claim. Consulting fees, royalties and practice-development services can give the manufacturer a way to reward use of its products. Evidence of work performed, compensation terms and implant volume shows what the arrangement actually purchased.

A physician-owned distributor places the surgeon on the selling side of implants ordered for that surgeon’s patients. The HHS inspector general’s alert on physician-owned entities focuses attention on how ownership returns relate to product use. Distributions tied to the owner’s cases, pressure to maintain implant volume and vendor records connect the financial arrangement to the hospital’s purchase.

For a reimbursement case, that connection belongs beside the clinical decision and the resulting claim. It explains why the product was chosen and who stood to earn from the choice.

How Is Medicare Fraud Detected?

Medical device reimbursement fraud can emerge when insiders or auditors connect manufacturer records with clinical and billing records. A claim can show the procedure while leaving the particular implanted product unidentified by its unique device identifier. Hospital records then supply the missing product and replacement details.

The HHS inspector general’s replacement-device audits depended on that comparison. The payment adjustment relied on credit information the hospital was supposed to report. When the credit was missing from the claim, the manufacturer and hospital records became central to finding the discrepancy.

Reimbursement staff see code recommendations and payer responses. Sales staff know what customers were told. Quality and regulatory staff hold product complaints, testing and reporting decisions. Hospital clinicians know what happened in the procedure, while purchasing and billing staff see the acquisition, credit and claim.

What Evidence Is Needed to Prove Fraud?

We work with you to connect the company’s instructions, what it knew and the claim the provider submitted. An internal coding instruction can explain what the manufacturer wanted billed. The customer’s claim shows whether that instruction reached the payer. A clinical or product record shows why the description was wrong.

Paradigm’s alleged coding discussion and Kyphon’s alleged reimbursement advice explain why an internal communication can matter alongside a payment record. We connect those parts with you so the case explains the instruction, the decision it changed and the claim that followed.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

Yes. A whistleblower can bring a False Claims Act case over a manufacturer’s knowing role in causing false government claims, even when a provider submits them. A qui tam case under the False Claims Act can pay 15% to 30% of what the government recovers.

The people who brought device cases have included sales representatives, reimbursement managers, quality staff, engineers, physicians and customers. Your role may explain why you recognize the discrepancy and where the other records sit. Our whistleblower experts assess that connection with you and build the case around how the company’s conduct reached the bill.

When You Know Where the Billing Advice Came From

If you know who told customers to use the code, admit the patient or omit the credit, speak with our whistleblower experts about the claims that followed. We work with you to build your strongest medical device reimbursement case and bring in healthcare fraud whistleblower lawyers who understand manufacturer conduct and provider billing. We stay beside you from that first account through the case.